Innovative Debt Solutions
Tailored Growth Capital
Announcements
Venture debt as an option for start-up companies
View Venture debt as an option for start-up companiesEurope’s Space Economy Needs a Broader Capital Stack
View Europe’s Space Economy Needs a Broader Capital StackClaret Capital Partners Strengthens Partnership with Paysend Through US$25M Follow-On Investment
View Claret Capital Partners Strengthens Partnership with Paysend Through US$25M Follow-On InvestmentClaret Capital Partners Extends €10M in Financing to Wellster Healthtech to Support European Expansion
View Claret Capital Partners Extends €10M in Financing to Wellster Healthtech to Support European ExpansionSamsung Ventures joins GridBeyond’s shareholder base as part of a €12M equity investment
View Samsung Ventures joins GridBeyond’s shareholder base as part of a €12M equity investmentClaret Capital Partners Invests €28M in Cinclus Pharma
View Claret Capital Partners Invests €28M in Cinclus PharmaClaret Capital Partners Announces Investment in U.S.-based ACT LAB
View Claret Capital Partners Announces Investment in U.S.-based ACT LABNeurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK® Commercial Expansion to treat Chronic Rhinitis
View Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK® Commercial Expansion to treat Chronic RhinitisThe GLP-1 Pill Race: Pharma’s New Frontier
View The GLP-1 Pill Race: Pharma’s New FrontierLiechtenstein’s spectrum award to Open Cosmos propels Europe in the space tele-communications infrastructure race.
View Liechtenstein’s spectrum award to Open Cosmos propels Europe in the space tele-communications infrastructure race.Claret Capital Partners Completes €35M Investment in Holidu to Fuel Growth and M&A
View Claret Capital Partners Completes €35M Investment in Holidu to Fuel Growth and M&AFund your growth while minimising dilution
Investing in Europe's leading disruptive businesses.
€
0
bn
Total capital deployed across Europe since inception.
€
0
bn
AUM
0
+
European SMEs backed across technology, life sciences and climate tech.
Selected investments:
FOUNDER & CEO CORNER
Further Reading
Claret News
19 May 2026
Claret wins Debt Funding Deal of the Year (<€10M) at the Irish Investor Awards 2026 with Neurent Medical
View Claret wins Debt Funding Deal of the Year (<€10M) at the Irish Investor Awards 2026 with Neurent Medical
Claret Insight
12 May 2026
Venture debt as an option for start-up companies
View Venture debt as an option for start-up companies
Claret Insight
5 May 2026
Europe’s Space Economy Needs a Broader Capital Stack
View Europe’s Space Economy Needs a Broader Capital Stack
Investment Announcement
31 Mar 2026
Claret Capital Partners Strengthens Partnership with Paysend Through US$25M Follow-On Investment
View Claret Capital Partners Strengthens Partnership with Paysend Through US$25M Follow-On Investment
Investment Announcement
23 Mar 2026
Claret Capital Partners Extends €10M in Financing to Wellster Healthtech to Support European Expansion
View Claret Capital Partners Extends €10M in Financing to Wellster Healthtech to Support European Expansion
Portfolio News
17 Mar 2026
Samsung Ventures joins GridBeyond’s shareholder base as part of a €12M equity investment
View Samsung Ventures joins GridBeyond’s shareholder base as part of a €12M equity investment
Investment Announcement
13 Mar 2026
Claret Capital Partners Invests €28M in Cinclus Pharma
View Claret Capital Partners Invests €28M in Cinclus Pharma
Investment Announcement
10 Mar 2026
Claret Capital Partners Announces Investment in U.S.-based ACT LAB
View Claret Capital Partners Announces Investment in U.S.-based ACT LAB
Portfolio News
11 Feb 2026
Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK® Commercial Expansion to treat Chronic Rhinitis
View Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK® Commercial Expansion to treat Chronic Rhinitis
Claret Insight
28 Jan 2026
The GLP-1 Pill Race: Pharma’s New Frontier
View The GLP-1 Pill Race: Pharma’s New Frontier
Portfolio News
14 Jan 2026
Liechtenstein’s spectrum award to Open Cosmos propels Europe in the space tele-communications infrastructure race.
View Liechtenstein’s spectrum award to Open Cosmos propels Europe in the space tele-communications infrastructure race.
Investment Announcement
14 Jan 2026